Patents by Inventor Marschall S. Runge
Marschall S. Runge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7267946Abstract: The present invention demonstrates that mitochondrial DNA damage occurs prior to, or simultaneous with, atherosclerotic lesion development, that aortic mitochondrial DNA damage increases with age, and that genotype and diet both influence the level of mitochondrial DNA damage. Hence, the present invention demonstrates that mitochondrial DNA damage occurs early in atherosclerosis, and may be an initiating event in atherogenesis, and provides methods to predict coronary atherosclerotic heart disease based upon the amount of mitochondrial DNA damage.Type: GrantFiled: April 10, 2001Date of Patent: September 11, 2007Assignee: Research Development FoundationInventors: Marschall S. Runge, Bennett VanHouten, Scott W. Ballinger
-
Publication number: 20030040495Abstract: The present invention demonstrates that mitochondrial DNA damage occurs prior to, or simultaneous with, atherosclerotic lesion development, that aortic mitochondrial DNA damage increases with age, and that genotype and diet both influence the level of mitochondrial DNA damage. Hence, the present invention demonstrates that mitochondrial DNA damage occurs early in atherosclerosis, and may be an initiating event in atherogenesis, and provides methods to predict coronary atherosclerotic heart disease based upon the amount of mitochondrial DNA damage.Type: ApplicationFiled: April 10, 2001Publication date: February 27, 2003Inventors: Marschall S. Runge, Bennett VanHouten, Scott W. Ballinger
-
Patent number: 6322974Abstract: The present invention demonstrates that mitochondrial DNA damage occurs prior to, or simultaneous with, atherosclerotic lesion development, that aortic mitochondrial DNA damage increases with age, and that genotype and diet both influence the level of mitochondrial DNA damage. Hence, the present invention demonstrates that mitochondrial DNA damage occurs early in atherosclerosis, and may be an initiating event in atherogenesis, and provides methods to predict coronary atherosclerotic heart disease based upon the amount of mitochondrial DNA damage.Type: GrantFiled: January 14, 1999Date of Patent: November 27, 2001Assignee: Research Development FoundationInventors: Marschall S. Runge, Scott W. Ballinger, Bennett VanHouten
-
Patent number: 5888974Abstract: A hybrid procoagulant factor VIII is produced by isolation and recombination of human and other nonhuman mammalian factor VIII subunits or domains, or by genetic engineering of the human and animal factor VIII genes. Subunits or domains of factor VIII that have been purified from human or animal plasma are isolated, and hybrid human/animal factor VIII is produced by (1) mixing either animal heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with animal light chain subunits, thereby producing human light chain/animal heavy chain and human heavy chain/animal light chain hybrid molecules; or by (2) mixing one or more domains of one species with one or more domains of the other species. These hybrid molecules are isolated by ion exchange chromatography.Type: GrantFiled: June 7, 1995Date of Patent: March 30, 1999Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5744446Abstract: Provided is a hybrid Factor VIII having a sequence of amino acids selected from the group of A2 domain fragments 373-540, 373-508, 445-508, 484-508, 404-508, 489-508 and 484-489 according to Seq ID NO 2 substituted with corresponding sequence of porcine or murine Factor VIII. Invention also relates to methods of treatment Factor VIII deficiency with said hybrid Factor VIII.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5663060Abstract: A hybrid human/animal coagulation factor VIII is produced by isolation and recombination of human and other non-human mammalian factor VIII subunits or domains, or by genetic engineering of the human and animal factor VIII genes. Subunits or domains of factor VIII that have been purified from human or animal plasma are isolated, and hybrid human/animal factor VIII is produced by (1) mixing either animal heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with animal light chain subunits, thereby producing human light chain/animal heavy chain and human heavy chain/animal light chain hybrid molecules; or by (2) mixing one or more domains of one species with one or more domains of the other species. These hybrid molecules are isolated by ion exchange chromatography.Type: GrantFiled: March 11, 1994Date of Patent: September 2, 1997Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5609869Abstract: Hybrid immunoglobulin-enzyme molecules are provided which are composed of antibodies, or derivatives or fragments thereof, which specifically bind an arterial or venous thrombus that are operably linked to the enzymatically active portions of thrombolytic enzymes such as plasminogen activators. In a preferred embodiment the hybrid molecules specifically bind to fibrin and have fibrinolytic activity. The hybrid molecules of the present invention may be produced by any means, including chemical conjugation, or by means of recombinant DNA, genetic engineering and/or hybridoma technology. Methods for making and using the molecules in diagnosis and therapy are also disclosed.Type: GrantFiled: May 30, 1995Date of Patent: March 11, 1997Assignee: The General Hospital CorporationInventors: Thomas Quertermous, Marschall S. Runge, Edgar Haber
-
Patent number: 5583209Abstract: A hybrid human/porcine coagulation factor VIII is produced by isolation and recombination of human and porcine factor VIII subunits, or by genetic engineering of the human and porcine factor VIII genes. Subunits of factor VIII that have been purified from human or porcine plasma are isolated, and hybrid human/porcine factor VIII is produced by mixing either porcine heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with porcine light chain subunits, thereby producing human light chain/porcine heavy chain and human heavy chain/porcine light chain hybrid molecules. These hybrid molecules are isolated by ion exchange chromatography. Alternatively, recombinant DNA methods are used to swap elements of porcine factor VIII for the corresponding elements of human factor VIII to produce hybrid human/porcine factor VIII.Type: GrantFiled: May 31, 1994Date of Patent: December 10, 1996Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge
-
Patent number: 5443827Abstract: A chimeric molecule that contains a fibrin-binding portion of an antibody covalently linked to an inhibitor of thrombin, which molecule is administered to inhibit thrombus formation and growth.Type: GrantFiled: May 3, 1993Date of Patent: August 22, 1995Assignees: President and Fellows of Harvard College, Emory UniversityInventors: Edgar Haber, Christoph Bode, Marschall S. Runge
-
Patent number: 5364771Abstract: A hybrid human/porcine coagulation factor VIII is produced by isolation and recombination of human and porcine factor VIII subunits, or by genetic engineering of the human and porcine factor VIII genes. Subunits of factor VIII that have been purified from human or porcine plasma are isolated, and hybrid human/porcine factor VIII is produced by mixing either porcine heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with porcine light chain subunits, thereby producing human light chain/porcine heavy chain and human heavy chain/porcine light chain hybrid molecules. These hybrid molecules are isolated by ion exchange chromatography. Alternatively, recombinant DNA methods are used to swap elements of porcine factor VIII for the corresponding elements of human factor VIII to produce hybrid human/porcine factor VIII.Type: GrantFiled: April 7, 1992Date of Patent: November 15, 1994Assignee: Emory UniversityInventors: John S. Lollar, Marschall S. Runge